middle.news
Noxopharm Advances HERACLES Trial, Clears Third SOF-SKN™ Dose Safely
10:39pm on Friday 29th of August, 2025 AEST
•
Biotechnology
Read Story
Noxopharm Advances HERACLES Trial, Clears Third SOF-SKN™ Dose Safely
10:39pm on Friday 29th of August, 2025 AEST
Key Points
Third dose cohort of SOF-SKN™ completed with positive safety results
Trial progresses to highest approved dose for next participant group
Double-blind design ensures rigorous, unbiased safety evaluation
SOF-SKN™ targets autoimmune diseases including cutaneous lupus erythematosus
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NOX
OPEN ARTICLE